RecruitingPhase 1NCT06825559

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Studying Sclerosing cholangitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zydus Therapeutics Inc.
Principal Investigator
Deven Parmar
Zydus Therapeutics Inc.
Intervention
Saroglitazar Magnesium 1 mg(drug)
Enrollment
6 target
Eligibility
18-80 years · All sexes
Timeline
2025 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06825559 on ClinicalTrials.gov

Other trials for Sclerosing cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Sclerosing cholangitis →

← Back to all trials